The Impact of COVID-19 is included in Cancer Monoclonal Antibodies Market Report. Buy it today to get an advantage.
Request the impact of COVID-19 on your product or industry
Cancer Monoclonal Antibodies Trends and Forecast
The future of the global cancer monoclonal antibodies market looks promising with opportunities in the hospital and research institute markets. The global cancer monoclonal antibodies market is expected to reach an estimated $153.7 billion by 2030 with a CAGR of 12.4% from 2024 to 2030. The major drivers for this market are increasing investment in research and development activities, rising inclination towards personalized medicines, and growing prevalance of cancer across the globe.
A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.
Cancer Monoclonal Antibodies by Segment
The study includes a forecast for the global cancer monoclonal antibodies by type, application, end use, and region.
Cancer Monoclonal Antibodies Market by Type [Shipment Analysis by Value from 2018 to 2030]:
• Humanized
• Human
• Chimeric
• Murine
Cancer Monoclonal Antibodies Market by Application [Shipment Analysis by Value from 2018 to 2030]:
• Blood Cancer
• Breast Cancer
• Lung Cancer
• Melanoma
• Colorectal Cancer
• Liver Cancer
• Others
Cancer Monoclonal Antibodies Market by End Use [Shipment Analysis by Value from 2018 to 2030]:
• Hospitals
• Research Institutes
• Others
Cancer Monoclonal Antibodies Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World
List of Cancer Monoclonal Antibodies Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies cancer monoclonal antibodies companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the cancer monoclonal antibodies companies profiled in this report include-
• F. Hoffmann-La Roche
• Bristol Myers Squibb
• Merck
• GlaxoSmithKline
• Johnson & Johnson
• Amgen
• Novartis
• AstraZeneca
• Eli Lilly
• AbbVie
Cancer Monoclonal Antibodies Market Insights
Lucintel forecasts that humanized is expected to witness the highest growth over the forecast period due to affordability, availability, and lesser production time for mouse monoclonal antibodies.
Within this market, hospitals will remain the largest segment due increasing prevalence of cancer along with growing number of patient hospitalizations.
North America will remain the largest region over the forecast period due to growing awarness towards advanced therapies, rising prevalence of cancer, and presence of major market players in the region.
Features of the Global Cancer Monoclonal Antibodies Market
Market Size Estimates: Cancer monoclonal antibodies market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Cancer monoclonal antibodies market size by type, application, end use, and region in terms of value ($B).
Regional Analysis: Cancer monoclonal antibodies market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different types, applications, end uses, and regions for the cancer monoclonal antibodies market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the cancer monoclonal antibodies market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
FAQ
Q1. What is the cancer monoclonal antibodies market size?
Answer: The global cancer monoclonal antibodies market is expected to reach an estimated $153.7 billion by 2030.
Q2. What is the growth forecast for cancer monoclonal antibodies market?
Answer: The global cancer monoclonal antibodies market is expected to grow with a CAGR of 12.4% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the cancer monoclonal antibodies market?
Answer: The major drivers for this market are increasing investment in research and development activities, rising inclination towards personalized medicines, and growing prevalance of cancer across the globe.
Q4. What are the major segments for cancer monoclonal antibodies market?
Answer: The future of the cancer monoclonal antibodies market looks promising with opportunities in the hospital and research institute markets.
Q5. Who are the key cancer monoclonal antibodies market companies?
Answer: Some of the key cancer monoclonal antibodies companies are as follows:
• F. Hoffmann-La Roche
• Bristol Myers Squibb
• Merck
• GlaxoSmithKline
• Johnson & Johnson
• Amgen
• Novartis
• AstraZeneca
• Eli Lilly
• AbbVie
Q6. Which cancer monoclonal antibodies market segment will be the largest in future?
Answer: Lucintel forecasts that humanized is expected to witness the highest growth over the forecast period due to affordability, availability, and lesser production time for mouse monoclonal antibodies.
Q7. In cancer monoclonal antibodies market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to growing awarness towards advanced therapies, rising prevalence of cancer, and presence of major market players in the region.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the cancer monoclonal antibodies market by type (humanized, human, chimeric, and murine), application (blood cancer, breast cancer, lung cancer, melanoma, colorectal cancer, liver cancer, and others), end use (hospitals, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
For any questions related to Cancer Monoclonal Antibodies Market, Cancer Monoclonal Antibodies Market Size, Cancer Monoclonal Antibodies Market Growth, Cancer Monoclonal Antibodies Market Analysis, Cancer Monoclonal Antibodies Market Report, Cancer Monoclonal Antibodies Market Share, Cancer Monoclonal Antibodies Market Trends, Cancer Monoclonal Antibodies Market Forecast, Cancer Monoclonal Antibodies Companies, write Lucintel analyst at email: helpdesk@lucintel.com. We will be glad to get back to you soon.
Table of Contents
1. Executive Summary
2. Global Cancer Monoclonal Antibodies Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Cancer Monoclonal Antibodies Market Trends (2018-2023) and Forecast (2024-2030)
3.3: Global Cancer Monoclonal Antibodies Market by Type
3.3.1: Humanized
3.3.2: Human
3.3.3: Chimeric
3.3.4: Murine
3.4: Global Cancer Monoclonal Antibodies Market by Application
3.4.1: Blood Cancer
3.4.2: Breast Cancer
3.4.3: Lung Cancer
3.4.4: Melanoma
3.4.5: Colorectal Cancer
3.4.6: Liver Cancer
3.4.7: Others
3.5: Global Cancer Monoclonal Antibodies Market by End Use
3.5.1: Hospitals
3.5.2: Research Institutes
3.5.3: Others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Cancer Monoclonal Antibodies Market by Region
4.2: North American Cancer Monoclonal Antibodies Market
4.2.2: North American Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others
4.3: European Cancer Monoclonal Antibodies Market
4.3.1: European Cancer Monoclonal Antibodies Market by Type: Humanized, Human, Chimeric, and Murine
4.3.2: European Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others
4.4: APAC Cancer Monoclonal Antibodies Market
4.4.1: APAC Cancer Monoclonal Antibodies Market by Type: Humanized, Human, Chimeric, and Murine
4.4.2: APAC Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others
4.5: ROW Cancer Monoclonal Antibodies Market
4.5.1: ROW Cancer Monoclonal Antibodies Market by Type: Humanized, Human, Chimeric, and Murine
4.5.2: ROW Cancer Monoclonal Antibodies Market by End Use: Hospitals, Research Institutes, and Others
5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by Type
6.1.2: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by Application
6.1.3: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by End Use
6.1.4: Growth Opportunities for the Global Cancer Monoclonal Antibodies Market by Region
6.2: Emerging Trends in the Global Cancer Monoclonal Antibodies Market
6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Cancer Monoclonal Antibodies Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Cancer Monoclonal Antibodies Market
6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
7.1: F. Hoffmann-La Roche
7.2: Bristol Myers Squibb
7.3: Merck
7.4: GlaxoSmithKline
7.5: Johnson & Johnson
7.6: Amgen
7.7: Novartis
7.8: AstraZeneca
7.9: Eli Lilly
7.10: AbbVie
.
Buy full report or by chapter as follows
Lucintel has been in the business of market research and management consulting since 2000 and has published over 1000 market intelligence reports in various markets / applications and served over 1,000 clients worldwide. This study is a culmination of four months of full-time effort performed by Lucintel's analyst team. The analysts used the following sources for the creation and completion of this valuable report:
In-depth interviews of the major players in this market
Detailed secondary research from competitors’ financial statements and published data
Extensive searches of published works, market, and database information pertaining to industry news, company press releases, and customer intentions
A compilation of the experiences, judgments, and insights of Lucintel’s professionals, who have analyzed and tracked this market over the years.
Extensive research and interviews are conducted across the supply chain of this market to estimate market share, market size, trends, drivers, challenges, and forecasts. Below is a brief summary of the primary interviews that were conducted by job function for this report.
Thus, Lucintel compiles vast amounts of data from numerous sources, validates the integrity of that data, and performs a comprehensive analysis. Lucintel then organizes the data, its findings, and insights into a concise report designed to support the strategic decision-making process. The figure below is a graphical representation of Lucintel’s research process.
Please sign in below to get report brochure - Cancer Monoclonal Antibodies Market Report.